Effects of steroid therapy on inflammatory cell subtypes in asthma

Rationale Airway inflammation in asthma is heterogeneous with different phenotypes. The inflammatory cell phenotype is modified by corticosteroids and smoking. Steroid therapy is beneficial in eosinophilic asthma (EA), but evidence is conflicting regarding non-eosinophilic asthma (NEA). Objectives To assess the inflammatory cell phenotypes in asthma after eliminating potentially confounding effects; to compare steroid response in EA versus NEA; and to investigate changes in sputum cells with inhaled corticosteroid (ICS). Methods Subjects undertook ICS withdrawal until loss of control or 28 days. Those with airway hyper-responsiveness (AHR) took inhaled fluticasone 1000 μg daily for 28+ days. Cut-off points were ≥/<2% for sputum eosinophils and ≥/<61% for neutrophils. Results After steroid withdrawal (n=94), 67% of subjects were eosinophilic, 31% paucigranulocytic and 2% mixed; there were no neutrophilic subjects. With ICS (n=88), 39% were eosinophilic, 46% paucigranulocytic, 3% mixed and 5% neutrophilic. Sputum neutrophils increased from 19.3% to 27.7% (p=0.024). The treatment response was greater in EA for symptoms (p<0.001), quality of life (p=0.012), AHR (p=0.036) and exhaled nitric oxide (p=0.007). Lesser but significant changes occurred in NEA (ie, paucigranulocytic asthma). Exhaled nitric oxide was the best predictor of steroid response in NEA for AHR (area under the curve 0.810), with an optimum cut-off point of 33 ppb. Conclusions After eliminating the effects of ICS and smoking, a neutrophilic phenotype could be identified in patients with moderate stable asthma. ICS use led to phenotype misclassification. Steroid responsiveness was greater in EA, but the absence of eosinophilia did not indicate the absence of a steroid response. In NEA this was best predicted by baseline exhaled nitric oxide.

[1]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[2]  C. Liu,et al.  Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism , 2008, Allergy.

[3]  A. Michils,et al.  Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients , 2008, European Respiratory Journal.

[4]  Pamela Ohman-Strickland,et al.  Respiratory effects of exposure to diesel traffic in persons with asthma. , 2007, The New England journal of medicine.

[5]  I. Pavord,et al.  Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma , 2007, Thorax.

[6]  J. Douwes,et al.  Innate immune activation in neutrophilic asthma and bronchiectasis , 2007, Thorax.

[7]  N. Wilson,et al.  Does sputum eosinophilia predict the response to systemic corticosteroids in children with difficult asthma? , 2007, Pediatric pulmonology.

[8]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[9]  O. Resta,et al.  Airway inflammation in subjects with gastro‐oesophageal reflux and gastro‐oesophageal reflux‐related asthma , 2006, Journal of internal medicine.

[10]  P. Paggiaro,et al.  Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. , 2006, Chest.

[11]  M. Kosinski,et al.  Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. , 2006, The Journal of allergy and clinical immunology.

[12]  R. Scott,et al.  Inflammatory subtypes in asthma: Assessment and identification using induced sputum , 2006, Respirology.

[13]  I. Pavord,et al.  The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  J. Cowan,et al.  Exhaled nitric oxide: a predictor of steroid response. , 2005, American journal of respiratory and critical care medicine.

[15]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[16]  I. Pavord,et al.  Is the neutrophil the key effector cell in severe asthma? , 2005, Thorax.

[17]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[18]  K. Chung,et al.  Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. , 2005, Respiratory medicine.

[19]  Q. Hamid,et al.  Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. , 2005, The Journal of allergy and clinical immunology.

[20]  I. Pavord,et al.  The influence of age on induced sputum differential cell counts in normal subjects. , 2004, Chest.

[21]  B. Lipworth,et al.  Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  D. Spodick,et al.  Electrocardiography in the Detection of Emphysema , 2004 .

[23]  A. Coats,et al.  Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro‐inflammatory cytokines and development of B19‐associated arthritis , 2004, Journal of medical virology.

[24]  Q. Hamid,et al.  Effect of HFA-flunisolide on peripheral lung inflammation in asthma. , 2003, The Journal of allergy and clinical immunology.

[25]  S. Anderson,et al.  Methods for “Indirect” challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols , 2003, Clinical reviews in allergy & immunology.

[26]  L. Boulet,et al.  Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids , 2002, European Respiratory Journal.

[27]  M. Pizzichini.  Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma? , 2002, European Respiratory Journal.

[28]  I. Pavord,et al.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids , 2002, Thorax.

[29]  J. Douwes,et al.  Non-eosinophilic asthma: importance and possible mechanisms , 2002, Thorax.

[30]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[31]  I. Pavord,et al.  Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants , 2002, Thorax.

[32]  P. Gibson,et al.  Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma , 2002, European Respiratory Journal.

[33]  K. J. Macleod,et al.  Smoking and airway inflammation in patients with mild asthma. , 2001, Chest.

[34]  R. Hancox,et al.  The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. , 2001, American journal of respiratory and critical care medicine.

[35]  P. Gibson,et al.  Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. , 2001, Chest.

[36]  D. Postma,et al.  Repeatability of bronchial hyperresponsiveness to adenosine-5′-monophosphate (AMP) by a short dosimeter protocol , 2001, Thorax.

[37]  A. Spanevello,et al.  Induced sputum cellularity. Reference values and distribution in normal volunteers. , 2000, American journal of respiratory and critical care medicine.

[38]  L. Bjermer,et al.  Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. , 2000, American journal of respiratory and critical care medicine.

[39]  P. O'Byrne,et al.  Induced sputum cell counts in healthy adults. , 2000, American journal of respiratory and critical care medicine.

[40]  C. Jenkins,et al.  Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. , 2000, The European respiratory journal.

[41]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[42]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[43]  R. Stockley,et al.  The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. , 1999, American journal of respiratory and critical care medicine.

[44]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.

[45]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[46]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[47]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.

[48]  F. Hargreave,et al.  Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. , 1996, The European respiratory journal.

[49]  S. Durham,et al.  Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. , 1996, American journal of respiratory and critical care medicine.

[50]  G. Cox,et al.  Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. , 1995, Journal of immunology.

[51]  Kwang Woo Kim,et al.  Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. , 1995, The Journal of allergy and clinical immunology.

[52]  S. Holgate,et al.  Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. , 1995, American journal of respiratory and critical care medicine.

[53]  H. Boushey,et al.  Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. , 1993, The American review of respiratory disease.

[54]  S. Anderson,et al.  Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .

[55]  E. Juniper,et al.  Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993, European Respiratory Journal.

[56]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[57]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[58]  S. Holgate,et al.  The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 5'-monophosphate and histamine in asthma. , 1991, The Journal of allergy and clinical immunology.

[59]  A. Woolcock,et al.  Rapid method for measurement of bronchial responsiveness. , 1983, Thorax.

[60]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[61]  H. Brown.  Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. , 1958, Lancet.

[62]  ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. , 2005, American journal of respiratory and critical care medicine.

[63]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[64]  F. Mitsunobu,et al.  Effects of long-term glucocorticoid therapy on bronchoalveolar cells in adult patients with bronchial asthma. , 1993, The Journal of asthma : official journal of the Association for the Care of Asthma.